Antabio

About:

Antabio is a private biopharmaceutical company developing antibacterial resistance-breakers in areas of highest medical need.

Website: https://antabio.com

Twitter/X: antabio

Top Investors: Bpifrance, European Innovation Council, Wellcome Trust, Omnes Capital, BNP Paribas Développement

Description:

Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. It develops stand-alone inhibitors of bacterial metalloenzymes that can be combined with various antibiotics to restore their activity against the most critical pathogens. The company's novel inhibitor of bacterial Metallo ß-lactamases (“MBLs”) which will be combined with a carbapenem to fill an important gap in the treatment of drug-resistant infections. They develop a novel, safe and efficacious inhibitor of bacterial Metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections. Antabio received a Wellcome Trust Seeding Drug Discovery Award. The company was founded in 2009 and is headquartered in Labege, France.